SPECT COINCIDENCE DETECTION EQUIPMENT ADDED TO FDG PET MEDICARE COVERAGE DECISION FOLLOWING ADAC PRESENTATION TO HCFA; INTERIM COVERAGE EFFECTIVE JAN. 1
This article was originally published in The Gray Sheet
Executive Summary
Adac's eleventh-hour presentation of data on coincidence imaging cameras to the Health Care Financing Administration won the company coverage of the technology under the agency's expansion of Medicare reimbursement for positron emission tomography. The revised policy allows coverage of fluorodeoxyglucose PET and coincidence detection imaging for certain lung cancer scanning procedures .
You may also be interested in...
Medicare Coverage Of Tumor Assays Should Be Monitored - MCAC Panel
Human tumor assay systems demonstrate clinical utility for certain patients and hold promise as a tool for treating a broad range of cancers, the Laboratory and Diagnostic Services Panel of the Medicare Coverage Advisory Committee agreed at its Nov. 15-16 meeting in Baltimore.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.